Flyrcado (flurpiridaz)
Research Synopsis
- Recent studies highlight the potential of Flyrcado (flurpiridaz F-18) as a promising PET radiotracer for assessing myocardial perfusion and diagnosing coronary artery disease (CAD).
- Flurpiridaz demonstrates strong myocardial extraction and stable washout patterns, providing improved accuracy in measuring myocardial blood flow (MBF).
- In a phase II trial, flurpiridaz showed significantly better image quality and diagnostic precision compared to traditional SPECT techniques, indicating its clinical viability.
- The novel tracer was able to quantify myocardial flow reserve (MFR) effectively, distinguishing between healthy and CAD patients with a notable degree of accuracy.
- Studies reveal that flurpiridaz facilitates both rest and stress evaluation within a single scan, significantly reducing examination time while maintaining diagnostic integrity.
- Research emphasizes the innovative motion correction techniques combined with flurpiridaz imaging, utilizing advanced algorithms to enhance the quality of cardiac images.
- The long half-life and favorable pharmacokinetics of flurpiridaz make it a preferred option for routine clinical use, overcoming limitations of existing short-lived tracers.
- Overall, flurpiridaz is positioned as a next-generation tool in nuclear cardiology, expected to enhance patient outcomes through more accurate diagnostics and assessments of cardiovascular health.
- Ongoing research continues to explore the full range of applications for flurpiridaz in both clinical and research contexts, further solidifying its role in contemporary cardiac imaging.
Flyrcado (flurpiridaz)
Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model.
London, UK
2 hours ago
1 Received
- The novel PET tracer flurpiridaz F 18 shows strong myocardial extraction and slow washout, allowing for potential simplified measurements of myocardial blood flow (MBF) after external injections.
- A study on pigs demonstrated that flurpiridaz F 18 retention and standardized uptake values (SUVs) taken shortly after injection highly correlate with accurate MBF measurements, suggesting they could serve as reliable indicators of myocardial flow reserve (MFR).
- However, while good correlations are found at earlier time points (5-12 minutes post-injection), retention and SUVs become less accurate at later times (10-20 minutes) for estimating flow during stress conditions.
$100 - $150
Hourly Rate
Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models.
London, UK
2 hours ago
1 Received
- Heart failure can affect cardiac sympathetic nerve function, and LMI1195 is a new PET imaging agent that targets the norepinephrine transporter (NET) to help identify individuals at risk for serious cardiac issues.* -
- When tested, LMI1195 showed comparable binding affinity and uptake kinetics to norepinephrine and 123I-MIBG, indicating similar effectiveness in tracking NET in cardiac tissue.* -
- LMI1195 demonstrated significantly higher heart-to-liver and heart-to-lung uptake ratios in animal studies, suggesting improved imaging clarity and potential for better assessment of cardiac health compared to traditional methods.*
$100 - $150
Hourly Rate
The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease.
London, UK
2 hours ago
1 Received
- Myocardial perfusion imaging (MPI) using thallium 201 or (99m)Tc agents is a key noninvasive method for detecting coronary artery disease (CAD), but it faces limitations like artifacts and suboptimal sensitivity.
- The new (18)F-based flurpiridaz F-18 uses positron emission tomography (PET) to address these issues, showing high heart uptake and effective identification of perfusion deficits.
- Early studies confirm flurpiridaz F-18’s safety and dosing requirements, positioning it as a next-generation MPI agent with superior imaging capabilities compared to traditional methods.
$100 - $150
Hourly Rate
Simplified quantification of myocardial flow reserve with (18)F-flurpiridaz: validation with microspheres in a pig model.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Automatic 3D registration of dynamic stress and rest (82)Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction.
London, UK
2 hours ago
1 Received
- The authors developed a new image-based registration method to correct for patient motion during cardiac PET/CT scans, specifically focusing on the effects of motion using two different perfusion agents: flurpiridaz F 18 and (82)Rb.
- They tested this method on 60 myocardial perfusion imaging datasets from 30 patients and measured motion using a cost function that combined global and local image features, while expert observers scored motion visually.
- The registration technique successfully reduced left ventricular motion with a 93% success rate, detecting maximum motion displacements averaging around 5.2 mm to 4.9 mm for flurpiridaz and 3.0 mm to 4.3 mm for (82)Rb
$100 - $150
Hourly Rate
Advances in PET myocardial perfusion imaging: F-18 labeled tracers.
London, UK
2 hours ago
1 Received
- Coronary artery disease is the leading cause of death in the USA, and accurate diagnosis and treatment are essential for improving patient outcomes.
- SPECT myocardial perfusion imaging (MPI) is the most commonly used diagnostic technique, but PET MPI is gaining traction due to its superior imaging capabilities.
- New F-18 labeled radiotracers with longer half-lives, such as flurpiridaz F 18, are being introduced to address the limitations of traditional PET tracers for better imaging practices in clinical settings.
$100 - $150
Hourly Rate
Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18.
London, UK
2 hours ago
1 Received
- - Rubidium-82 is a key radiotracer used in PET myocardial perfusion imaging (MPI), offering better image quality compared to SPECT MPI due to higher spatial resolution and reduced scatter effects.
- - PET imaging not only allows detailed assessment of the heart’s blood flow during stress but also delivers valuable functional data that SPECT cannot provide.
- - Advancements in imaging technology, such as better gating methods and new radiopharmaceuticals like flurpiridaz F 18, are expected to further enhance the quality and utility of PET MPI in clinical settings.
$100 - $150
Hourly Rate
Properties of an ideal PET perfusion tracer: new PET tracer cases and data.
London, UK
2 hours ago
1 Received
- An ideal PET tracer for heart imaging should be highly absorbable by the heart muscle, provide clear images, measure blood flow accurately, and not require an on-site cyclotron for production.
- While radiotracers like nitrogen-13 ammonia and oxygen-15 water need a cyclotron, rubidium-82 can be locally sourced but has limitations like low extraction efficiency and high costs.
- Flurpiridaz F 18, a new tracer in development, shows promising results with better image quality, quicker testing, and reduced radiation exposure in comparison to current tracers, making it a strong candidate for heart health assessment.
$100 - $150
Hourly Rate
Single-scan rest∕stress imaging (18)F-labeled flow tracers.
London, UK
2 hours ago
1 Received
- The authors introduce a new technique that allows for the measurement of both rest and stress myocardial blood flow in a single, short scan session.
- This method utilizes long-lived tracers and treats the rest-stress assessment as one continuous process, effectively eliminating issues caused by leftover radioactivity.
- Tests showed that the innovative approach using (18)F-Flurpiridaz produced highly accurate and precise blood flow estimates, potentially achievable in just 20-30 minutes.
$100 - $150
Hourly Rate
LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment.
London, UK
2 hours ago
1 Received
- The study investigates the relationship between regional cardiac sympathetic denervation (RCSD) and noradrenaline transporter (NAT) function, using a new PET imaging agent called LMI1195.
- LMI1195 was tested for its ability to detect RCSD in a rabbit model and was compared to other substances, showing significant potential for imaging.
- The findings indicate that RCSD not only can be imaged effectively with LMI1195 but also contributes to increased cardiac risks when treated with the antiarrhythmic drug dofetilide.
$100 - $150
Hourly Rate
Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.
London, UK
2 hours ago
1 Received
- This phase II trial evaluated the safety and diagnostic performance of flurpiridaz F 18 in PET myocardial perfusion imaging (MPI), comparing it to the traditional Tc-99m SPECT MPI, focusing on image quality and accuracy in detecting coronary artery disease (CAD).
- Results showed that PET imaging with flurpiridaz F 18 had significantly better image quality and diagnostic certainty, with higher sensitivity for detecting CAD compared to SPECT.
- Flurpiridaz F 18 was found to be safe for use, with overall findings indicating it could be a superior option for myocardial perfusion imaging in clinical settings.
$100 - $150
Hourly Rate
The role of PET quantification in cardiovascular imaging.
London, UK
2 hours ago
1 Received
- - Positron Emission Tomography (PET) is used for detailed assessment of myocardial perfusion and function, allowing doctors to measure heart blood flow during both stress and rest conditions in a single exam.
- - PET's ability to measure myocardial blood flow and coronary flow reserve is crucial for diagnosing severe coronary diseases and assessing heart viability, especially with the integration of advanced software for analyzing PET data.
- - New tracers and improved scanning technologies, along with computerized analysis, enhance the accuracy of detecting coronary issues and have the potential to identify at-risk atherosclerotic plaques, improving overall cardiovascular imaging.
$100 - $150
Hourly Rate
Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.
London, UK
2 hours ago
1 Received
- Absolute quantitation of myocardial blood flow (MBF) using the novel PET radiotracer flurpiridaz shows promise for analyzing coronary artery disease (CAD), overcoming limitations of existing radiotracers.
- A new quantitation method demonstrated differing MBF and myocardial flow reserve (MFR) in healthy subjects compared to those with CAD, with significant differences observed based on arterial stenosis severity.
- Flurpiridaz allows for precise measurement of MBF in various cardiac conditions, effectively distinguishing between normal perfusion and stress-inducible myocardial ischemia.
$100 - $150
Hourly Rate
Cardiac PET perfusion tracers: current status and future directions.
London, UK
2 hours ago
1 Received
- PET myocardial perfusion imaging (MPI) is a noninvasive method for detecting coronary artery disease, but its use is limited by issues with current tracers that have short half-lives and require special equipment for production.
- Current tracers like (82)Rb, (15)O water, and (13)N ammonia have drawbacks such as poor image resolution and impracticality for use with exercise stress testing.
- The development of a new (18)F-labeled PET tracer, Flurpiridaz F 18, shows promise due to its longer half-life, better image quality, and favorable characteristics such as high myocardial extraction and stability over time, marking it as a potentially ideal alternative.
$100 - $150
Hourly Rate
In vitro and in vivo structure-property relationship of (68)Ga-labeled Schiff base derivatives for functional myocardial pet imaging.
London, UK
2 hours ago
1 Received
- The study aimed to develop (68)Ga-labeled PET tracers based on Schiff base amines for better imaging of myocardial damage compared to traditional SPECT imaging with (99m)Tc-sestamibi.
- Fifteen Schiff bases were synthesized, showing varying lipophilicity and consistent cellular uptake in cardiomyocytes, which decreased when the membrane potential was disrupted, highlighting their potential for detecting ischemic heart tissue.
- Results indicated that the best (68)Ga-based tracers achieved myocardial uptake comparable to (99m)Tc-sestamibi while offering the advantage of improved spatial resolution in PET imaging.
$100 - $150
Hourly Rate
Positron-emitting myocardial blood flow tracers and clinical potential.
London, UK
2 hours ago
1 Received
- Positron-emitting myocardial flow radiotracers like (15)O-water, (13)N-ammonia, and (82)Rubidium, used with PET scans, are becoming popular for accurately diagnosing coronary artery disease (CAD) and providing insights into cardiovascular outcomes.
- (82)Rubidium is particularly advantageous as it can be sourced from a strontium generator, eliminating the need for a cyclotron, which limits the use of (15)O-water and (13)N-ammonia to specific centers.
- The new F-18-labeled radiotracer flurpiridaz offers a long half-life and may enhance the application of PET for assessing myocardial blood flow, potentially transforming personalized treatment
$100 - $150
Hourly Rate
Cardiac applications of PET.
London, UK
2 hours ago
1 Received
- - Routine use of cardiac PET imaging is on the rise but hasn’t fully replaced SPECT studies; most PET tracers are not widely available due to production challenges.
- - 18F-FDG PET has high sensitivity for assessing heart viability and has taken over from Tl-201 SPECT, while other PET tracers demonstrate greater accuracy in detecting coronary artery disease (CAD) compared to SPECT.
- - Novel 18F-labeled perfusion tracers being tested show promising results for diagnosing CAD, and 18F-FDG PET can also identify inflammation in various heart-related conditions like endocarditis and sarcoidosis.
$100 - $150
Hourly Rate
Dual-Gated Motion-Frozen Cardiac PET with Flurpiridaz F 18.
London, UK
2 hours ago
1 Received
- - A new PET radiotracer, Flurpiridaz F 18, was tested in a phase II clinical trial for its ability to enhance cardiac imaging by correcting for both respiratory and cardiac motion in patients.
- - The study involved 16 patients and utilized a 4-ring PET scanner, comparing various imaging methods to determine the best combination of gating techniques—including motion-frozen (MF) algorithms for improved image quality.
- - Results showed that dual-gated imaging provided significantly better wall/cavity contrast and contrast-to-noise ratios than other imaging methods, indicating it enhances image resolution and is effective for cardiac perfusion evaluation.
$100 - $150
Hourly Rate
Impact of motion and partial volume effects correction on PET myocardial perfusion imaging using simultaneous PET-MR.
London, UK
2 hours ago
1 Received
- PET is a key imaging technique for evaluating heart blood flow, but heart movement and certain technical limitations can distort image quality and accuracy.
- A study aimed to create a correction method using simultaneous PET-MR to address these issues and tested it with a new tracer on healthy pigs.
- Results showed that the motion correction significantly improved image quality, reducing the apparent wall thickness and increasing the myocardium-to-blood concentration ratios, demonstrating the effectiveness of combining motion and spatial resolution corrections.
$100 - $150
Hourly Rate
Direct parametric reconstruction in dynamic PET myocardial perfusion imaging: in vivo studies.
London, UK
2 hours ago
1 Received
- Dynamic PET myocardial perfusion imaging (MPI) uses tracer kinetic modeling to measure absolute myocardial blood flow (MBF), but traditional methods struggle with low signal-to-noise ratios (SNR).
- A new study evaluates a direct parametric reconstruction approach for dynamic PET MPI, which shows improved SNR by reconstructing kinetic parameters from raw data rather than from delayed images.
- The study involved dynamic PET scans of healthy pigs following a radiotracer injection, comparing parametric maps generated through both traditional indirect methods and the proposed direct method for evaluating MBF.
$100 - $150
Hourly Rate